Publication List English

2020/05/28
A novel orexin antagonist from a natural plant was discovered using zebrafish behavioural analysis

2019/10/15
C3orf70 Is Involved in Neural and Neurobehavioral Development

2019/09/22
Generation of a Triple-Transgenic Zebrafish Line for Assessment of Developmental Neurotoxicity during Neuronal Differentiation

2019/07/17
Aging-associated microstructural deterioration of vertebra in zebrafish

2019/03/18
Zebrafish yolk sac microinjection of thalidomide for assessment of developmental toxicology

tTwo isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.

                     
1993/01/29

Masuoka H, Ito M, Sugioka M, Kozeki H, Konishi T, Tanaka T, Nakano T.
Biochem Biophys Res Commun. 1993 Jan 29;190(2):412-7.

Abstract

We examined the inhibitory effects of vesnarinone, a new cardiotonic agent, on human cyclic nucleotide phosphodiesterase (PDE). Vesnarinone selectively inhibited the activity of human cardiac cGMP-inhibited PDE with a Ki value of 8.5 microM. The inhibition of human cardiac cGMP-inhibited PDE by vesnarinone was not competitive but was of the mixed type with respect to cAMP. Although the activities of the cGMP-inhibited PDE from human heart, aorta, platelets, and kidney were inhibited to the same extent by cGMP, enoximone, and cilostazole, vesnarinone inhibited the activities of cardiac and kidney cGMP-inhibited PDE with 10 times greater potency than those of platelet and aorta cGMP-inhibited PDE. These results suggest that there exist, in human tissues, two isoforms of cGMP-inhibited PDE that can be distinguished by reference to the inhibitory effects of vesnarinone.

ŠÖ˜AƒŠƒ“ƒN

Pubmed